Low Serum Adiponectin Predicts 10-Year Risk of

[Guest guest]

Our aim of the present work was to study the effect of serum adiponectin on incident diabetes

and HbA1c values. We measured baseline serum adiponectin levels in a nested case-control

selection (n = 140) of the Whitehall II Cohort. Participants (mean [sD] age 50.9 [6.3] years)

had no prevalent diabetes or CHD at baseline. Cases (n = 55) had incident diabetes according

to an oral glucose tolerance test during followup (mean: 11.5 ± 3.0 years). Adiponectin levels

were lower among cases (9.3 ì g / ml, 3.2 [median; IQR] vs. 10.5; 3.6, p = 0.01). The risk of incident

diabetes decreased by 11 % (p = 0.03) for 1 ì g / ml higher adiponectin levels. Higher adiponectin

levels were associated with lower HbA1c at follow- up (p < 0.05). Both associations were stable

to adjustment for age, sex, body mass index, systolic blood pressure, and serum lipids, and

for the case of HbA1c, also for C-reactive protein (all p < 0.05). The observed robust, prospective

associations support that adiponectin is an independent predictor of diabetes and the degree of

glycaemic impairment

 

http://www2.warwick.ac.uk/fac/med/staff/cappuccio/publications/horm_res_met_2009_wii.pdf